AML14.3D10/CCCKR3 Clone 16 (ATCC® CRL-12079)

Organism: Homo sapiens, human  /  Cell Type: leukocyte  /  Disease: acute myeloid leukemia (FAB M2)

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Cell Type leukocyte
Product Format frozen
Culture Properties suspension
Biosafety Level 1
Disease acute myeloid leukemia (FAB M2)
Age 68 years
Gender male
Applications
The AML14.3D10 line was transfected with a plasmid designated pBJ/NEO/CCCKR3. The plasmid expresses a full length cDNA encoding CCR3 cloned into the expression vector pBJ/NEO [U.S. Pat.
The cells may be used in assays to screen and identify compounds that bind to the eosinophil eotaxin receptor.
Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma [U.S. Pat.
The line was cloned by limiting dilution and a subclone named AML14.3D10 that maintains an advanced eosinophilic phenotype was selected [PubMed: 9474744].
The AML14 human myeloid leukemic cell line was established in 1992 from a 68-year-old man who presented with FAB M2 acute myeloid leukemia [PubMed: 9474744].
Images
Derivation
The AML14 human myeloid leukemic cell line was established in 1992 from a 68-year-old man who presented with FAB M2 acute myeloid leukemia [PubMed: 9474744]. The line was cloned by limiting dilution and a subclone named AML14.3D10 that maintains an advanced eosinophilic phenotype was selected [PubMed: 9474744]. The AML14.3D10 line was transfected with a plasmid designated pBJ/NEO/CCCKR3. The plasmid expresses a full length cDNA encoding CCR3 cloned into the expression vector pBJ/NEO [U.S. Pat. 6,271,347]. The clone was selected for neomycin resistance [U.S. Pat. 6,271,347]. The cells may be used in assays to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma [U.S. Pat. 6,271,347].
Clinical Data
The AML14 human myeloid leukemic cell line was established in 1992 from a 68-year-old man who presented with FAB M2 acute myeloid leukemia [PubMed: 9474744].
male
Comments
The AML14 human myeloid leukemic cell line was established in 1992 from a 68-year-old man who presented with FAB M2 acute myeloid leukemia [PubMed: 9474744]. The line was cloned by limiting dilution and a subclone named AML14.3D10 that maintains an advanced eosinophilic phenotype was selected [PubMed: 9474744]. The AML14.3D10 line was transfected with a plasmid designated pBJ/NEO/CCCKR3. The plasmid expresses a full length cDNA encoding CCR3 cloned into the expression vector pBJ/NEO [U.S. Pat. 6,271,347]. The clone was selected for neomycin resistance [U.S. Pat. 6,271,347]. The cells may be used in assays to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma [U.S. Pat. 6,271,347].
Complete Growth Medium RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES and 1.0 mM sodium pyruvate and supplemented with 0.05 mM 2-mercaptoethanol, 2 mg/ml G418 and 10% fetal bovine serum
Subculturing
Protocol: The cells are very fragile. Do not allow the cell to achieve a density greater than 8 X 10(5) viable cells/ml. Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(4) viable cells/ml.
Interval: Maintain cell density between 2 X 10(4) and 4 X 10(5) viable cells/ml.
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Population Doubling Time 15 hours
Name of Depositor Merck & Co., Inc.
Year of Origin 1992
References

Baumann MA, Paul CC. The AML14 and AML14.3D10 cell lines: a long-overdue model for the study of eosinophils and more. Stem Cells 16: 16-24, 1998. PubMed: 9474744

Daugherty BL, et al. Eosinophil eotaxin receptor. US Patent 6,271,347 dated Aug 7 2001

Finke PE, et al. Cyclopentyl modulators of chemokine receptor activity. US Patent 6,506,777 dated Jan 14 2003

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation
References

Baumann MA, Paul CC. The AML14 and AML14.3D10 cell lines: a long-overdue model for the study of eosinophils and more. Stem Cells 16: 16-24, 1998. PubMed: 9474744

Daugherty BL, et al. Eosinophil eotaxin receptor. US Patent 6,271,347 dated Aug 7 2001

Finke PE, et al. Cyclopentyl modulators of chemokine receptor activity. US Patent 6,506,777 dated Jan 14 2003